Oricula Therapeutics Secures $2M NIH Grant to Further Develop Medicine to Preserve Hearing

Oricula Therapeutics, LLC, a biotech company uniquely positioned to introduce medicines to preserve hearing and balance, announced that it has received a Phase 2 Grant of $2.06 million through the Small Business Innovation Research (SBIR) Program by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The award supports completion of the preclinical workup for their lead clinical compound (ORC-13661) and submission of an FDA Investigational New Drug (IND) application to support subsequent clinical trials. If successful, Oricula's product will be the first medicine to be FDA-approved to protect the inner ear from permanent hearing loss caused by aminoglycoside antibiotics.

Further details may be found here.

Published on: 
February 9, 2016


University of Washington, Box 357923, CHDD Clinic Building, Room CD176; Seattle, WA 98195-7923. 206.685.2962, FAX 206.616.1828, bloedel@u.washington.edu